Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE The activation of oncogenic mitogen-activated protein kinase cascade via mutations in BRAF is often observed in human melanomas. 31571292 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial. 31157737 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a <i>BRAF<sup>V600E</sup></i> mutation. 31416844 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Upregulation of MC1R expression was determined in BRAF<sup>V600E</sup> cells (A2058) and BRAF wild-type melanoma cells (MEWO) by quantitative real-time polymerase chain reaction, flow cytometry, and receptor-ligand binding assays. 31318566 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. 30979895 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE As the selective inhibitor of BRAF kinase, vemurafenib exhibits effective antitumor activities in patients with V600 BRAF mutant melanomas. 30717768 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Here, we explored the role of miRNAs in melanoma acquired resistance to BRAFi. 31227006 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly. 31123282 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Our analysis of data has demonstrated that combined BRAF and MEK inhibitor-based treatment is associated with an increased risk of all-grade rash and a decreased risk of all-grade and high-grade HK, SP, alopecia, cSCC, HFS, and PR compared with single BRAF inhibitor alone in melanoma patients. 30501438 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Novel studies investigating the biologic characteristics of acral MM reported variable results: the overall mutational rates ranged respectively between 8.5% and 23% for KIT, between 3.6% and 33.3% for BRAF and between 3% and 47% for NRAS in ALMs. 29512974 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha. 30997532 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE There is no standard oncological treatment available for metastatic UM patients, and BRAF/MEK and immune checkpoint inhibitors show disappointing results when compared to cutaneous melanoma (CM). 31200439 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. 31223037 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE We present the case of a 58-year-old man with a completely regressed metastatic melanoma who developed a second melanoma with concomitant involution of papillomatous nevi under BRAF inhibitors treatment. 30944613 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. 30959471 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Discrete transcriptional states were defined in cell lines and melanoma patient specimens that predicted initial sensitivity to BRAF inhibition and the potential for effective re-challenge following resistance. 31594749 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma. 31425480 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE We identified six melanoma lines harboring BRAF fusions representative of the clinical cases reported in the literature. 31618628 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. 30254376 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33.6 months in the phase III COLUMBUS trial. 30652516 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Fifty percent of melanomas are BRAF mutation positive. 31261023 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Here, we show that Bap1 deletion in melanocytes cooperates with the constitutively active, oncogenic form of BRAF (BRAF<sup>V600E</sup> ) and UV to cause melanoma in mice, albeit at very low frequency. 30156010 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Inhibition of the mitogen-activated protein kinase (MAPK) pathway as well as programmed death 1 receptor (PD-1) blockade was shown to prolong overall survival (OS) in patients with advanced B-Raf proto-oncogene (BRAF)-mutant melanoma. 30806748 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAF<sup>V600</sup> mutation-positive melanoma compared with cytotoxic chemotherapy. 30580112 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE The management of melanoma has been rapidly advancing with new classes of agents, including immune checkpoint and BRAF inhibitors. 31064886 2019